* Jaguar Health Inc reported a quarterly adjusted loss of $1.05 per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-33.00. The lone analyst forecast for the quarter was for a loss of $2.37 per share.
* Revenue rose 10.5% to $3.11 million from a year ago; analysts expected $3.94 million.
* Jaguar Health Inc's reported EPS for the quarter was a loss of $1.05.
* The company reported a quarterly loss of $9.85 million.
* Jaguar Health Inc shares had fallen by 19.3% this quarter and lost 88.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 113.5% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"
Wall Street's median 12-month price target for Jaguar Health Inc is 14.50 This summary was machine generated from LSEG data November 13 at 02:17 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -2.37 -1.05 Beat
Jun. 30 2024 -1.20
Mar. 31 2024 -1.80 -4.20 Missed
Comments